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Abstract: Radiation resistance is a significant challenge in the treatment of breast cancer in humans.
Human breast cancer is commonly treated with surgery and adjuvant chemotherapy/radiotherapy,
but recurrence and metastasis upon the development of therapy resistance results in treatment failure.
Exosomes are extracellular vesicles secreted by most cell types and contain biologically active cargo
that, when transferred to recipient cells, can influence the cells’ genome and proteome. We propose
that exosomes secreted by radioresistant (RR) cells may be able to disseminate the RR phenotype
throughout the tumour. Here, we isolated exosomes from the human breast cancer cell line, MDA-MB-
231, and the canine mammary carcinoma cell line, REM134, and their RR counterparts to investigate
the effects of exosomes derived from RR cells on non-RR recipient cells. Canine mammary cancer
cells lines have previously been shown to be excellent translational models of human breast cancer.
This is consistent with our current data showing that exosomes derived from RR cells can increase cell
viability and colony formation in naïve recipient cells and increase chemotherapy and radiotherapy
resistance, in both species. These results are consistent in cancer stem cell and non-cancer stem cell
populations. Significantly, exosomes derived from RR cells increased the tumoursphere-forming
ability of recipient cells compared to exosomes derived from non-RR cells. Our results show that
exosomes are potential mediators of radiation resistance that could be therapeutically targeted.
Keywords: breast cancer; exosomes; chemoresistance; radioresistance; comparative oncology;
One Health
1. Introduction
Breast cancer is the most common female malignancy and the leading cause of cancer-
related deaths in women [1,2]. Similarly, naturally occurring canine mammary tumours
are the most common cause of death in intact female dogs and have been proposed as a
comparative model of the human disease [3]. Canine mammary tumours have a similar
genetic predisposition, histopathology, disease progression and clinical outcome to the
human disease. Human breast cancer is commonly classified into molecularly distinct
subtypes: normal breast-like, HER2+, luminal A, luminal B and triple negative. These
subtypes differ in clinical outcomes, patient survival and treatment strategy. However,
there is gene expression heterogeneity within these subtypes and breast cancer can be
considered as a spectrum of diseases. Kumar et al., 2012 [4] utilised microarray technology
to highlight a 163-gene expression signature associated with prognosis, highlighting that,
in the context of gene expression, this disease is highly heterogenous and individualised.
Assessing the global gene expression and proteomic profiles of each individual patient
and applying that information to a database of available treatment options may be more
successful, in terms of survival rates, than following a rigid treatment plan based on tumour
subtype [5]. This method of patient-specific therapy assignment would be more efficient in
terms of time, expense and patient side effects and may be applicable in both human and
veterinary medicine.
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The emergence of resistance to key modalities, including chemotherapy and radiother-
apy, and the subsequent re-initiation of tumour growth and relapse represent a significant
clinical problem, often with limited treatment options and increased mortality. Understand-
ing the underlying molecular mechanisms driving therapy resistance could help to identify
potential biomarkers to track the emergence of resistance and novel therapeutic targets.
Tumours comprise a heterogenous mix of cell populations including cancer stem cells
(CSCs) and non-CSCs, which make up the bulk of the tumour. CSCs are long-lived cells that
drive tumourigenesis as they can self-renew and differentiate into other cellular subtypes.
Breast CSCs are inherently resistant to conventional chemotherapy and radiotherapy [6].
Therefore, the relative size of a CSC pool within a tumour may influence the intrinsic
radioresistance of that tumour. Radiation treatment will eliminate the majority of cancer
cells; however, CSCs will survive and be able to re-initiate tumour growth and tumour
cell repopulation leading to patient relapse [7]. The development of acquired therapy
resistance can also occur due to selective pressures imposed by cancer therapies that can
result in advantageous mutations in newly forming cancer cells and lead to increased
survival by, for example, the activation of epithelial-to-mesenchymal transition (EMT),
enhanced DNA damage repair and enhanced elimination of cytotoxic content from within
the cancer cell [8] including the active chemotherapeutic agents or the reactive oxygen
species produced during radiotherapy treatment [9].
Exosomes have been implicated in the acquisition of therapy resistance [10,11]. Exo-
somes are nanovesicles secreted from most living cells. They have a size range between of
30–150 nm in diameter, and they contain a biologically active cargo consisting of nucleic
acids, miRNAs, proteins and lipids, encapsulated within their double membrane [12].
The outer surface of the membrane contains integrins, tetraspanins and cell signalling
receptors [13]. The content of exosomes is reflective of the parental cell from which it
is derived, and under non-diseased states, the role of exosomes is to mediate cell-to-cell
communication [14,15]. As the formation of exosomes within the parental cell results in
the incorporation of the contents of the parental cell, the exosome cargo can reflect the
development and progression of the diseased state of the parental cell. Further research
has shown that the active content of exosomes can result in phenotypic and genotypic
changes in recipient cells. In cancer, exosomal transfer can occur between developing
cancer cells, and between cancer cells and stromal cells, and can have a range of functions,
for example, developing cancer cells can communicate via exosomes to programme stromal
cells to provide nourishment in the form of amino acids and carbon [16–18]. As well as
programming surrounding stromal cells to provide a nurturing environment for cancer
cells, exosomes can also promote metastasis and mediate organotropism [19,20].
Exosomes have been shown to play a pivotal role in therapy resistance in
humans [21,22], but the role of exosomes in canine therapy resistance has not yet been
studied. Exosomes derived from human breast cancer cells have been shown to shuttle
chemotherapeutic agents out of the cell [23], and chemotherapy-resistant breast cancer
cells can transfer p-glycoprotein protein pumps to chemotherapy-sensitive breast cancer
cells to allow the active removal of the chemotherapeutic agents [24]. However, the role of
exosomes in the development of radiotherapy resistance in breast cancer cells and the CSC
population is poorly understood, and the mechanisms by which exosomes can mediate
chemoresistance cannot be directly applied to the development of radioresistance. We
hypothesise that exosomes derived from radioresistant (RR) cells can disseminate the
RR phenotype to non-RR cancer cells. In this study, we isolated exosomes from the hu-
man breast cancer cell line, MDA-MB-231, and the canine mammary carcinoma cell line,
REM134, and their RR counterparts to investigate the effects of exosomes derived from
RR cells on non-RR recipient cells. Our data show that exosomes derived from RR cells,
compared to exosomes derived from non-RR cells, can increase cell viability and colony
formation in recipient cells and increase chemotherapy and radiotherapy resistance. These
results are consistent in CSC and non-CSC populations. Our results show that exosomes
are potential mediators of RR that could be therapeutically targeted. Future research could
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focus on the profiling the exosomal cargo to identify emerging markers of radioresistance.
These biomarkers could be monitored throughout treatment to optimise patient-specific
treatment plans for anticancer interventions.
2. Materials and Methods
2.1. Cell Culture
The cell lines used in this study were the human breast cancer cell line, MDA-MB-
231, and the canine mammary carcinoma cell line, REM134 [25]. Radioresistant MDA-
MB-231 and REM134 cell lines were gifted by Dr. Mark Gray [26]. RR cell lines were
established over several weeks by gradually irradiating the non-RR parental cell lines
with increasing doses of Gray (Gy). MDA-MB-231 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) + 1 g/L D-glucose, L-glutamine + pyruvate (Gibco Life
Technologies, Invitrogen, UK). REM134 cells were grown in DMEM + 4.5 g/L D-glucose,
L-glutamine—pyruvate (Gibco Life Technologies, Invitrogen, UK). All cell culture media
were supplemented with 10% exosome-depleted FBS and 1% penicillin and streptomycin.
Cells were maintained at 37 ◦C in 5% CO2 in a humidified incubator. FBS was depleted
of exosomes by ultracentrifugation in an SW32 Ti rotor (Beckman Coulter, IN, USA) at
12,000× g for 18 h at 4 ◦C.
2.2. Radiation Treatment
To maintain the RR phenotype, RR cells were irradiated with 12 Gy every 3–4 weeks.
Briefly, cells were grown until 70% confluence and, after standard trypsinisation, were
resuspended as single cells in 10 mL of the appropriate media and immediately irradiated in
the gamma cell irradiator (Gammacell 1000 Elite, Best Theratronics, Ottawa, ON, Canada) in
50 mL falcon tubes. After irradiation, cells were transferred into a T75 flask and maintained
as previously described.
2.3. Exosome Isolation
Cells were seeded in T175 flasks and grown until 70% confluence. Cells were washed
in PBS, and all media were replaced with 10 mL of exosome-free DMEM and incubated
for 24 h. The medium was removed and centrifuged at 500× g for 10 min to remove cell
debris. The supernatant was then filtered through a 0.22 µm filter and ultracentrifuged
at 120,000× g for 90 min at 4 ◦C in an SW41 ultracentrifuge rotor (Beckman Coulter, IN,
USA) with swing buckets. The supernatant was removed, and the exosome pellet was
resuspended in 1 mL filtered PBS and stored at −70 ◦C until further use.
2.4. Exosome Quantification
Exosomes were lysed with RIPA buffer (50 mM Tris pH 6.8, 150 mM NaCl, 1 mM
EDTA, 1% NP40) by adding 3:1 volume of RIPA buffer to the exosome sample and mixing
thoroughly. The samples were incubated for 30 min on ice and then centrifuged at 13,000× g
for 5 min at 4 ◦C. Supernatants were transferred to 1.5 mL Eppendorf tubes and stored at
−70 ◦C. The protein concentration of samples was determined by a Bradford assay. BSA
standards at 0.1, 0.25, 0.5, 1, 2, 5 and 10 mg/mL were used as controls. Then, 1 µL of
BSA standards were added to designated wells of a 96-well plate in duplicate, and 1 µL
of protein samples were loaded in triplicate. Following this, 200 µL of Bradford reagent
(Bio-Rad Laboratories, Watford, UK) was added to each well and mixed by pipetting. The
plate was incubated at room temperature for 2 min. Absorbance at 595 nm was determined
using the Victor3 plate reader (Perkin Elmer, Beaconsfield, UK) and the relative protein
concentration of the samples was determined by comparing them to the BSA standards.
2.5. Transmission Electron Microscopy
Freshly isolated exosomes in 10 µL PBS were added in a 1:1 ratio with 2% paraformalde-
hyde and immediately processed for transmission electron microscopy (TEM). Briefly, 5 µL
of sample was placed on formvar-coated grids and incubated for 20 min at room tempera-
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ture. Grids were washed in 100 µL of PBS plus 50 µL of 1% glutaraldehyde for 5 min and
then incubated with 100 µL of ddH2O for 2 min. Wash steps were repeated eight times in
total. After washing, 50 µL of 1% uranyl-oxalate solution (pH 7) was added to the grid for
5 min, then 50 µL of methyl cellulose-UA was added for 10 min on ice. The excess fluid was
removed by blotting, and the grids were air dried for 5 to 10 min. Samples were viewed on
a JEM-1400 Plus TEM (Jeol, Welwyn, UK) operating at 80 kV. Representative images were
collected on an OneView camera (Gatan, Pleasanton, CA, USA). These experiments were
carried out at King’s Buildings at The University of Edinburgh.
2.6. Nanoparticle Tracking Analysis
Exosomes were analysed by nanoparticle tracking analysis (NanoSight LM10, Malvern
Panalytical, Malvern, UK) to determine the size range and distribution. Briefly, 1 mL of
diluted exosome sample (1:50–1:100) was loaded on to the NanoSight machine, and particle
concentration was determined and diluted in the range of 4 × 108–12 × 108 particles/mL.
Parameters were set at a detection rate of 15,000 particles per minute for capture settings,
and the smallest vesicle size was set at 30 nm, with analysis performed by NanoSight
software version 2.3 (Malvern Panalytical, Malvern, UK). The rate at which exosomes were
produced per cell per hour was calculated by dividing the total number of exosomes by the
total number of cells after exosome harvesting and then dividing by the number of hours
over which the sample was collected.
2.7. Exosome Treatment
For exosome treatment, cells were seeded depending on cell type and experimental
conditions. Generally, exosomes were added at a concentration of 50 µg/mL. To determine
this concentration, 10 µL of isolated exosomes were lysed, and their protein concentration
was quantified as in Section 2.4. From that concentration, we calculated the volume of
isolated exosomes required to make up a solution at 50 µg/mL in exosome-free media. All
exosome solutions were made up fresh prior to treatment. Controls were generated with
PBS vehicle instead of exosomes.
2.8. Cell Viability Assay
Cells were seeded in 96-well plates at 500 cells per well. Exosomes were added at
the indicated concentrations 24 h after seeding. Cell viability was determined 72 h post-
treatment using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Hampshire,
UK) according to the manufacturer’s instructions. Luminescence was measured by a
Victor3 multilabel plate reader (Perkin Elmer, Beaconsfield, UK). Data were averaged and
normalised against the average signal of the PBS control samples.
2.9. Colony Fromation Assay
MDA-MB-231 and MDA-MB-231 RR cell lines were trypsinised and seeded as single
cells at 50 cells per well in a 6-well plate. REM134 and REM134 RR were trypsinised and
seeded as single cells at 1000 cells per well in a 6-well plate. Immediately after seeding,
either PBS (vehicle control), 50 µg/mL exosomes derived from non-RR cells or exosomes
derived from RR cells were added to the appropriate well. All plates were incubated as
previously described until colonies formed in the vehicle control (approximately 10 days).
To stain the colonies, each well was washed with 5 mL PBS and then incubated with
5 mL of 100% methanol for 5 min at room temperature. The methanol was removed, and
plates were air dried. Colonies were then stained with a Giemsa stain (20% Giemsa stain
(Sigma-Aldrich, Gillingham, UK) plus 80% ddH2O) for 20 min at room temperature. After
staining, the plates were then washed twice with water and air dried. All colonies were
counted and normalised to the control.
In experiments to determine the effect of exosomes derived from RR cells on the
colony-forming ability after treatment with radiation, cells were seeded at 20,000 cells
in 1 mL of medium in a 12-well plate and incubated for 24 h with either PBS, 50 µg/mL
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exosomes derived from non-RR cells or 50 µg/mL exosomes derived from RR cells. Cells
were then seeded as single cells as described above. In addition, MDA-MB-231 CSCs and
MDA-MB-231 RR CSCs were seeded at 750 cells in 3 mL media, and REM134 CSCs and
REM134 RR CSCs were seeded at 1000 cells in 3 mL media. Single cells were immediately
irradiated at either 0, 2.5 or 5 Gy. Colonies were allowed to form and were processed as
described above.
2.10. Chemosensitivity Assays
MDA-MB-231 and MDA-MB-231 RR cells were seeded at 500 cells/50 µL per well in a
96-well plate. REM134 and REM134 RR cells were seeded at 1000 cells/50 µL per well in
a 96-well plate. CSCs were seeded at 1000 cells/50 µL per well. Cells were incubated for
24 h before treating with 25 µL exosomes (50 µg/mL). Cells were then treated 12 h later
with a dose titration of doxorubicin at the indicated concentrations in 25 µL. Cell viability
was determined 72 h post-treatment with doxorubicin as described above.
2.11. Tumoursphere-Forming Assay
Cells were seeded at 20,000 cells/mL in 1 mL of exosome-free FBS DMEM media in
12-well plates and treated with either PBS, 50 µg/mL of exosomes derived from non-RR
cells or 50 µg/mL of exosomes derived from RR cells and incubated for 24 h. Follow-
ing incubation, MDA-MB-231 and MDA-MB-231 RR cells were seeded as single cells at
3000 cells per well, and REM134 and REM134 RR were seeded at 6000 cells per well, in
3 mL N2 media in 6-well low-attachment plates (Corning, Flintshire, UK). All samples
were triplicated. N2 media was supplemented every 48 h with human EFG and human
FGF at 10 ng/mL (Peptrotech, London, UK). Sphere formation was monitored for 7 days.
Tumourspheres over 50 µm in diameter were counted in five random fields of vision using
an Axiovert 40 CFL microscope (Zeiss, Hallbergmoos, Germany) with images taken at 5×
and 10× magnification and size measurements recorded by Axiovision software version
4.7.2 (Zeiss, Hallbergmoos, Germany).
2.12. Migration Assay
Cells were seeded at 20,000 cells in 1 mL media per well in a 12-well plate and
treated with either PBS or corresponding exosomes derived from either non-RR or RR
cells at the indicated concentration and incubated for 24 h. Cells were then seeded into
Ibidi® (Munich, Germany) chamber slides according to the manufacturer’s instructions.
Briefly, cells were trypsinised and seeded at varying concentrations: MDA-MB-231 at
4.5 × 105/well; MDA-MB-232 RR at 4.75 × 105/well; REM134 at 3.45 × 105/well; and
REM134 RR at 3.75 × 105/well and incubated until confluent. Once confluent, each insert
was removed to leave a gap. Then, 1 mL of media was added to each well and the width
of the gap was measured at six points using the Axiovert 40 CFL microscope with an
AxioCAM HRm camera (Zeiss, Hallbergmoos, Germany) and pictures were taken at 5×
magnification at set time points until the gap was closed. The migration distance was
recorded at stated time points with measurements by Axiovision software version 4.7.2.
Percentage migration was calculated as (A−B)/B), with A being the size of the gap at 0 h,
and B being the gap at the designated time point.
2.13. Statistical Analysis
Data were analysed for normality using the Anderson−Darling normality test and
the appropriate parametric/non-parametric test was chosen to determine statistical signifi-
cance. All statistical analyses were performed using Minitab 19 software, with statistical
significance being defined as p ≤ 0.05.
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3. Results
3.1. Isolation of Exosomes from Canine and Human Breast Cancer Cell Lines and Their Derived
RR Counterparts
Radioresistant cell lines MDA-MB-231 RR and REM134 RR were derived by exposing
parental cells to increasing doses of radiation every week up until there was limited cell
death at 8 Gy [27]. RR cells are morphologically distinct from non-RR parental cells: RR cells
have extended cytoplasmic extensions and a spindle-like morphology (Figure 1A(ii,iv))
compared to non-RR cells (Figure 1A(i,ii)). Exosomes were isolated from all cell lines by
ultracentrifugation and visualised using TEM. All exosomes exhibited the characteristic
“cup shape” morphology [21] (Figure 1B(i–iv)) and expected size distribution as analysed
by nanoparticle tracking analysis (NTA) (Figure 1C(i–iv)). NTA was also used to calculate
the rate of exosome production per cell per hour and showed that RR cells produced more
exosomes than non-RR cells. REM 134 RR cells and MDA-MB-231 RR produced approxi-
mately sixfold and threefold more exosomes than their non-RR counterparts, respectively
(Figure 1D).
3.2. Exosomes Isolated from RR Cells Increased the Survival of Recipient Cells Compared to
Exosomes Isolated from Non-RR Cells
To determine the effect of exosomes on cell viability, cells were seeded in 96-well plates,
incubated for 24 h and then treated with exosome dilutions of 10, 20, 30, 50 and 75 µg/mL.
Cell viability was determined 72 h after treatment. Our data show that exosomes derived
from RR cell lines resulted in a significant increase in cell viability, which appeared to be
dose dependant, resulting in an increase in cell viability from 100% to 150% (Figure 2A).
To compliment the cell viability assay, we also performed colony formation assays. Single
cells were immediately treated with either 50 or 100 µg/mL of the corresponding exosomes
and incubated until colonies were visible. Exosomes derived from MDA-MB-231 RR and
REM134 RR cell lines resulted in a significant increase in the number of colonies compared
to both PBS control and exosomes derived from non-RR exosomes (Figure 2B). Based on
these results, we selected 50 µg/mL of exosomes to be used in further experiments.
Figure 1. Cont.
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Figure 1. Isolation of exosomes from canine and human breast cancer cell lines and their derived
isogenic RR counterparts. (A) Cell morphology of (i) REM134, (ii) REM134 RR, (iii) MDA-MB-231
and (iv) MDA-MB-231 RR cells. Scale bar represents 100 µm. (B) Visualisation, using TEM, of
exosomes isolated from (i) REM134, (ii) REM134 RR, (iii) MDA-MB-231 and (iv) MDA-MB-231 RR
cells. Scale bar represents 200 nm. Characterisation of exosomes using NTA to measure (C) particle
distribution from (i) REM134 cells, (ii) REM134 RR, (iii) MDA-MB-231 and (iv) MDA-MB-231 RR
and (D) rate of exosome production per cell per hour. Data are representative of three independent
experiments.





Figure 2. Exosomes isolated from RR cell lines increased the survival of recipient cells. Analysis of (A) cell viability and (B)
colony-forming ability were assayed after (i) REM134, (ii) REM134 RR, (iii) MDA-MB-231 and (iv) MDA-MB-231 RR cells
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were treated with the indicated dose of exosomes isolated from either corresponding non-RR or RR cells. All results are
relative to the appropriate PBS control. Three repeats were performed and analysed by a two-sample t test. Error bars
indicate ±SD. * p ≤ 0.05, ** p ≤ 0.01; *** p ≤ 0.001, **** p ≤ 0.00001.
3.3. Exosomes Isolated from RR Cells Enhanced the Migration Potential of Recipent Cells
To investigate the effect of exosomes derived from RR cells on the migration potential
of REM134 and MDA-MB-231 cells and their RR derivatives, we utilised a 2D scratch assay.
Here, cells were incubated with 50 µg/mL of exosomes for 24 h to allow for exosome uptake
prior to seeding into a chamber cell with an ibidi insert. Removal of the insert created a
defined wound in the cell monolayer. Closure of the wound was measured at the indicated
time points until the wound was fully closed (Figure 3). The vehicle control showed that
RR cells migrate inherently faster than non-RR cells: non-RR REM134 cells closed the
wound 56 h after injury (Figure 3(Ai)) compared to RR REM134 cells, which closed the
wound 24 h after injury (Figure 3(Bi)). Similar results, albeit less striking, were obtained for
the MDA-MB-231 cell line, whereby non-RR cells closed the wound at 28 h (Figure 3(Ci))
compared to RR cells, which closed the wound at 24 h after injury (Figure 3(Cii)). Exosomes
derived from both non-RR and RR cells enhanced the migration potential of recipient cells;
however, this effect was more prominent in cells treated with RR exosomes. In non-RR
REM134 cells treated with exosomes isolated from non-RR cells, the wound closed at 52 h
compared to 48 h for those treated with exosomes derived from RR cells (Figure 3(Ci)).
These results were significantly different compared to the control and between treatment
groups, such as at 24 h (p = 0.0000) for the effect of exosomes derived from RR cells when
compared to the control and exosomes derived from non-RR cells. In RR REM134 cells
treated with exosomes isolated from non-RR cells, the wound closed at 12 h compared to
8 h for those treated with exosomes derived from RR cells (Figure 3(Cii)). These results
were significantly different compared to the control and between treatment groups, such
as at 8 h (p = 0.0000) for the effect of exosomes derived from RR cells when compared to
the control and exosomes derived from non-RR cells. The human cell line showed similar
results, in non-RR MDA-MB-231 cells treated with exosomes isolated from non-RR cells,
the wound closed at 24 h compared to 12 h for those treated with exosomes derived from
RR cells (Figure 3(Ciii)). These results were significantly different compared to the control
and between treatment groups, for example at 8 h (p = 0.0000) for the effect of exosomes
derived from RR cells when compared to the control and exosomes derived from non-RR
cells. In RR MDA-MB-231 cells treated with exosomes isolated from non-RR cells, the
wound closed at 12 h compared to 8 h for those treated with exosomes derived from RR
cells (Figure 3(Ciii)). These results were significantly different compared to the control
and between treatment groups such as at the time point of 8 h (p = 0.0000) for the effect
of exosomes derived from RR cells when compared to the control and exosomes derived
from non-RR cells.
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with the indicated dose titration of doxorubicin. Cell viability was determined 72 h post-
treatment (Figure 4A). Exosomes isolated from REM134 RR cells resulted in a significant
increase in cell viability of both types of recipient cells, REM134 RR (Figure 4(Ai)) and
REM134 non-RR (Figure 4(Aii)) compared to exosomes isolated from non-RR cells and PBS
controls, such as at 0.001 µM (p < 0.00001) in both the REM134 and the REM134 RR cell
line. The exosomes derived from the non-RR MDA-MB-231 cell line did not result in a
significant increase in percentage cell viability when compared to the PBS control when
added to the MDA-MB-231 cell line (Figure 4(Aiii)), except in the MDA-MB-231 RR cell
line (Figure 4(Aiv)) at the concentration of 0.001 µM (p < 0.01).
Figure 4. Exosomes isolated from RR cells increased the resistance of recipient cells to doxorubicin and ionising radiation.
(A) Chemosensitivity to increasing doses of doxorubicin was determined for (i) REM134, (ii) REM134 RR, (iii) MDA-MB-231
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and (iv) MDA-MB-231 RR cells. Cells were seeded for 24 h with exosomes (50 µg/mL) isolated from either non-RR or RR
corresponding cell lines prior to treatment with the indicated dose of doxorubicin. Cell viability was assayed 72 h after
doxorubicin treatment. (B) Colony-forming ability after treatment with 0, 2.5 or 5 Gy was determined for (i) REM134,
(ii) REM134 RR, (iii) MDA-MB-231 and (iv) MDA-MB-231 RR cells. All cell lines were pretreated with exosomes (50 µg/mL)
isolated from either non-RR or RR corresponding cell lines for 24 h prior to irradiation. Three repeats were performed,
and significance was determined by a two-sample t test. Error bars indicate ±SD. * p ≤ 0.05, ** p ≤ 0.01; *** p ≤ 0.001,
**** p ≤ 0.00001.
To assay the effect of exosomes isolated from RR cells on the resistance of recipient
cells to radiotherapy, we utilised a colony formation assay to assess cell survival and
clonogenic growth. Here, non-RR or RR cells were incubated with 50 µg/mL of exosomes
isolated from either non-RR or RR cells prior to seeding as single cells at a low density and
immediately irradiating at the indicated doses. The number of colonies were counted after
10 days. Exosomes isolated from RR cells significantly increased the colony-forming ability
of recipient cells after irradiation at 2.5 and 5 Gy compared to exosomes isolated from
non-RR cells or the PBS vehicle control (Figure 4B). This effect was more striking in the
non-RR cells treated with exosomes isolated from RR cells in both canine (Figure 4(Bi)) and
human (Figure 4(Biii)) cell lines, compared to RR cells treated with exosomes isolated from
RR cell lines (Figure 4B(ii,iv)). Our results show that exosomes derived from the RR breast
cancer cell lines can alter the phenotype of recipient cells and enhance their resistance to
doxorubicin and irradiation.
3.5. Exosomes Isolated from RR Cells Can Alter the Phenotype of CSCs
CSCs are inherently more resistant to conventional cancer therapies than surrounding
bulk (non-CSC) cancer cells. To determine the effect of exosomes isolated from RR cells on
recipient CSCs, we enriched for CSCs using an established tumoursphere assay from all cell
lines [28]. CSCs were pre-incubated with exosomes isolated from either RR, non-RR cells
or PBS control for 24 h prior to treatment with the indicated dose titration of doxorubicin.
Cell viability was assayed 72 h later. Our results show that exosomes isolated from RR cells
significantly increased the percentage of cell viability for all recipient CSCs when compared
to exosomes isolated from non-RR cells or the PBS vehicle control (Figure 5A). These results
were consistent regardless of RR status and both in REM134 cell lines (Figure 5A(i,ii)) and
in MDA-MB-231 cell lines (Figure 5A(iii,iv)). We also noted that PBS-treated RR CSCs were
inherently more resistant to doxorubicin at all indicated doses than non-RR CSCs, and this
was consistent in both cell lines (Figure 5A).
To investigate the effect of exosomes isolated from RR cells on recipient CSCs af-
ter radiotherapy, we assayed their colony-forming ability after irradiation. CSCs were
pretreated with exosomes for 24 h prior to seeding as single cells at a low density and
then immediately irradiated at 0, 2.5 and 5 Gy. The number of colonies were counted
after approximately 10 days. Exosomes isolated from the REM134 RR and MDA-MB-231
RR cell lines significantly increased the number of colonies formed and, therefore, the
radioresistance of all recipient CSCs compared to treatment with exosomes derived from
non-RR cells or the PBS control (Figure 5B). To a much lesser extent, recipient cells treated
with exosomes isolated from non-RR cell lines produced relatively more colonies after
irradiation treatment compared to the PBS control. This was statistically significant in
both non-RR REM134 CSCs (p < 0.031 at 2.5 Gy and p < 0.003 at 5 Gy) and RR REM134
CSCs (p < 0.00001) (Figure 5B(i,ii)) and for non-RR MDA-MB-231 CSCs at 2.5 Gy (p < 0.05)
(Figure 5(Biii)). Significantly, our results show that exosomes derived from RR cells can
change the radioresistance potential of recipient CSCs.
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3.6. Exosomes Derived from RR Cells Increased the Size of the CSC Pool
To observe the effect of exosomes isolated from RR cells on the tumoursphere-forming
ability of recipient cells, REM134, REM134 RR, MDA-MB-231 and MDA-MB-231 RR cells
were incubated with 50 µg/mL of exosomes isolated from the indicated cell lines for 24 h,
cells were then seeded into low-attachment plates with N2 media to allow the formation of
3D tumourspheres. REM134 and REM134 RR tumourspheres were counted after 5 days.
MDA-MB-231 and MDA-MB-231 RR tumourspheres were counted after 17 days. Our
results showed that exosomes isolated from both non-RR cell lines (MDA-MB-231 and
REM134) and RR cell lines (MDA-MB-231 RR and REM134 RR) significantly increased
tumoursphere-forming capacity, both in the number of tumourspheres formed and in the
relative size of individual tumourspheres (Figure 6A(i,iv)). Recipient cells of exosomes
isolated from non-RR cells produced approximately twice as many tumourspheres com-
pared to the PBS control. This was consistent in all cell lines (Figure 6B(i,iv)). REM134 and
REM134 RR recipient cells treated with exosomes isolated from RR cells produced a 3-fold
and 4.5-fold increase in tumoursphere formation compared to PBS control, respectively
(Figure 6B(i,ii)). Both MDA-MB-231 and MDA-MB-231 RR recipient cells treated with
exosomes isolated from RR cells produced approximately 2.5-fold increase in tumour-
sphere formation compared to PBS control (Figure 6B(iii,iv)). Recipient cells treated with
exosomes isolated from RR cells produced significantly larger tumourspheres compared to
those receiving exosomes isolated from non-RR cells or the PBS control (Figure 6C(i,iv)).
Interestingly, recipient cells treated with exosomes isolated from non-RR cells produced
significantly larger tumourspheres compared to the PBS control (Figure 6C(i,iv)). Together,
our results indicate that exosomes derived from RR cell types can significantly increase the
tumoursphere-forming ability of recipient cells and enhance the overall survival of CSCs,
indicating that exosomes derived from RR cell lines may increase the size and hardiness of
the CSC pool, and this may drive treatment failure in a clinical setting.
Figure 6. Cont.
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Figure 6. Exosomes isolated from RR cells enhanced sphere-forming ability. Spheres were characterised by (A) cell morphology,
(B) number of spheres and (C) size of spheres. (i) REM134, (ii) REM134 RR, (iii) MDA-MB-231 and (iv) MDA-MB-231 RR cells
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were treated with 50 µg/mL exosomes isolated from either non-RR or RR corresponding cell lines for 24 h prior to setting
up the sphere assay. REM134 and REM134 RR spheres were grown for 7 days, and MDA-MB-231 and MDA-MB-231 RR
spheres were grown for 17 days prior to analysis. Three repeats were performed, data were analysed by a two-sample t test
and size data was analysed by a Wilcoxon signed rank test. Error bars indicate ±SD. **** p ≤ 0.00001.
4. Discussion
Radiotherapy treatment is critical in the management of human breast cancers, with
up to 94% of invasive breast cancer patients receiving radiotherapy treatment plans after
surgery in conjugation with chemotherapy [29]. Despite progress made in the precision
delivery of radiation and personalised radiotherapy schedules, the development of ra-
dioresistance in clinical settings is a significant clinical challenge, which ultimately leads to
relapse and metastasis [27]. The tumour microenvironment plays an important role, driving
tumour progression and therapeutic response. Exosomes are small extracellular vesicles,
containing a large array of active biomolecules that are secreted by different cells into the
extracellular matrix of the tumour microenvironment. They are then internalised by recipi-
ent cells and then release their content to mediate gene expression and protein activity [12].
Cellular stresses, including radiation and hypoxia, affect exosome secretion, composition,
abundance and potential binding to recipient cells [28–31]. Previous studies have shown
that radiation can enhance the release of exosomes and change their molecular composition
and that exosomes are capable of transferring radiation-induced effects to non-irradiated
cancer cells, therefore, potentially mediating radiation bystander effects [32,33]. Most of
these reports have mainly focused on pre- and postradiation changes in exosomal proteins
and miRNAs rather than on the mechanisms involved in these changes or their effect on
biological functions [30,34,35]. In these studies, exosomes are usually harvested between 1
and 96 h after irradiation treatment [35]. In general, there is a lack of radioresistant model
systems to facilitate elucidating the mechanisms underlying the development of radioresis-
tance. In our lab, we previously developed and extensively characterised novel in vitro
radioresistant cell lines from human breast cancer (MCF-7, ZR-751 and MDA-MB-231) and
canine mammary carcinoma (REM-134) cell lines [26,36]. We found that the radioresistance
phenotype was maintained long term, even in the absence of radiation exposure, and
concluded that the acquisition of radioresistance was not transient [26]. In this study, we
utilised these radioresistant model systems to show that exosomes derived from established
RR breast cancer cell lines are capable of changing the phenotype of non-RR recipient cells
and inducing radioresistance within 24 h of uptake. Our data suggest that radioresistance
is transmittable via exosomes and that, once acquired and established, radioresistance
could potentially spread throughout a tumour and beyond. This may be reflective of
the observation that any factor affecting the phenotype of a donor cell likely affects the
molecular composition of the exosome released by that cell. Our results are consistent
with previous studies that investigated the functional role of exosomes in the response of
exosomes to radiation exposure. These studies showed that exosomes secreted from head
and neck cancer cells within 24 h of irradiation increased the proliferation, survival and
migration potential of both non-irradiated and irradiated recipient cells [31,37]. Similarly,
exosomes isolated from irradiated glioblastoma cells enhanced the migration phenotype
of recipient cells, and molecular profiling revealed an abundance of molecules important
for cell migration [38]. However, in these studies, as well as our study, conditioned media
collected from irradiated cells prior to exosome isolation were not used as a positive control
to confirm that exosomes can mediate this effect within the context of a more complex
secretome including other extracellular vesicles.
To date, no studies have mapped changes in exosome composition through the process
of acquiring radioresistance. In future studies, we aim to utilise our panel of established RR
cell lines to compare the cargo of exosomes derived from RR cells and non-RR cells. Current
knowledge in radiation-induced changes in exosome cargo is limited and refers mainly
to proteomic changes. There are several studies showing that exosomes derived from
irradiated cells can increase the levels of proteins involved in transcription and translation,
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chaperones, ubiquitin-related proteins and proteosome components and downregulate the
proteins associated with response to stress, immunity, cell adhesion and immunity [31,35].
Future research should also focus on the minutiae of exosome uptake and processing
to determine what drives the selective uptake of exosomes derived from radioresistant
cells/cancer stem cell populations, as it would be beneficial to identify the fate of exosomes
derived from radioresistant cells once they are internalised by recipient cells. Do all
recipient cells take up exosomes equivalently? Or are subsets of cells primed to take up
exosomes secreted by irradiated cells? Can we block this interaction using either small-
molecule compound inhibitors or neutralising antibodies? Do all recipient cells respond
the same once donor exosomes have been taken up? These are interesting questions that
warrant further investigation.
The use of exosomes as a minimally invasive platform for evaluating the circulating
biomarkers of a multitude of physiological and pathological processes (including cancer,
pregnancy disorders, cardiovascular diseases and immune responses) is gaining traction.
Exosomes exist in almost all body fluids and are very stable as they are encapsulated by
lipid bilayers, this enhances the clinical applicability of exosomes. Exosomes and their
cargo are also representative of parental cells and contain more biological information
than cell-free DNA or conventional serum-based biomarkers. Within the context of solid
cancers, although solid biopsy is still the gold standard for pathological diagnosis and basis
for treatment, the use of serum-based exosomes as biomarkers of cancer has been demon-
strated in gliomas [39–41], liver cancers [42,43], endometrial cancer [44] and gastrointestinal
cancers [45,46]. Exosomes in urine have also been investigated for their possible use in the
diagnosis and prognostication of prostate cancer [47,48]. As the production of exosomes
and their composition is altered by radiation treatment, exosomes could potentially be
used as non-invasive diagnostic markers for radiosensitivity and to monitor the emergence
of radioresistance.
Breast cancers are highly heterogeneous and contain a small subset of CSCs. CSCs are
inherently more resistant to radiation treatment that non-CSCs and more likely to survive
treatment and re-initiate tumour growth [27]. Here, we show that exosomes isolated
from RR breast cancer cells have similar effects on both CSCs and non-CSCs, notably
conferring resistance to radiation. Interestingly, exosomes isolated from both RR and non-
RR cells increased the sphere-forming ability of recipient cells, but this was enhanced by
the former significantly more, indicating that exosomes isolated from RR breast cancer cells
may increase the size of the CSC pool. We also showed that exosomes isolated from RR
cells increased the migratory ability of recipient cells, indicating that that these exosomes
activate an EMT, which is associated with cellular plasticity and the acquisition of CSC
characteristics [49]. Although, we have shown that exosomes isolated from RR breast
cancer cells confer a radioresistance phenotype on recipient cells and that recipient cells
have enhanced sphere-forming ability, we have not unequivocally shown that the increased
radioresistance is due to an increased proportion of inherently resistant CSCs. Further
studies will focus on confirming whether recipient cells of exosomes isolated from RR
cells activate an EMT and whether this process is the predominant underlying molecular
mechanism driving emerging radiation resistance in naïve cells.
In this study, we compared human and canine breast cancer cells as canine mammary
cancer is considered as an excellent translational model of human breast cancer. Naturally
occurring mammary tumours are the most frequently diagnosed cancer in bitches, and
these tumours represent 50% of all canine tumours, of which 50% are malignant [50].
The main treatment option for dogs is surgery alone due to a lack of receptor status
evaluation or molecular subtype classification. Previously, in our lab, we compared the RR
REM-134 cell line with a panel of RR human cell lines to investigate the mechanisms of
acquired radioresistance and identified a number of similarities including the expression
of epithelial and mesenchymal genes and WNT, PI3K and MAPK pathway activation [26].
Here, we demonstrate that exosomes isolated from human and canine RR cell lines have
similar functional effects on recipient cells and that the process of potentiating exosome-
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mediated radioresistance is comparable in humans and dogs. We believe that a “One
Health” approach is crucial to unpick tumourigenesis and to develop future treatment
strategies that will benefit both species.
5. Conclusions
Our study provides compelling evidence that exosomes can serve as an effective com-
munication tool in the development of radioresistance and can confer pro-survival signals
and promote the radioresistant phenotype to non-radioresistant cells. This study indicates
a functional role for exosomes within our models in the dissemination of aggressive cancer
characteristics. Further studies are required to map the cargo of exosomes derived from RR
cells and to identify and validate potential therapeutic targets to halt the perpetuation of
acquired radioresistance throughout a tumour.
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